Search Result

Results for "

drug-resistant+bacteria

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Antibiotic (3) Apoptosis (1) Autophagy (1) Bacterial (17) Bcl-2 Family (1) Beta-lactamase (5) DNA/RNA Synthesis (2) Fungal (2) GLUT (1) Influenza Virus (1) JNK (1) Lactate Dehydrogenase (1) PPAR (1) Reactive Oxygen Species (ROS) (2) SOD (1) Topoisomerase (2)
By Research Areas:	Cancer (1) Infection (18) Metabolic Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1939

Cyclo(L-Leu-L-Pro) Cyclo(L-prolyl-L-leucyl)	Fungal Bacterial Influenza Virus	Infection
Cyclo(L-Leu-L-Pro) is a cyclic dipeptide with broad-spectrum antibacterial, antiviral and antifungal activities. Its biological activity is highly dependent on the stereoconfiguration and is widely present in microbial metabolites. Cyclo(L-Leu-L-Pro) efficiently and specifically inhibits the production of aflatoxin by Aspergillus flavus. The cis configuration of Cyclo(L-Leu-L-Pro) (cis-cyclo(L-Leu-L-Pro)) has broad-spectrum antibacterial activity against multi-drug resistant bacteria and significantly inhibits the influenza A virus H3N2 .

HY-W040128

Kanamycins sulfate	Antibiotic Autophagy JNK Bcl-2 Family	Infection
Kanamycins sulfate is a blood-brain barrier-permeable JNK1 and Bcl-2 modulator as well as an antibiotic, with broad-spectrum antibacterial, and biofilm-inhibiting activities, and it induces autophagy. Kanamycins sulfate promotes Bcl-2 phosphorylation to upregulate autophagy levels, triggering changes such as mitochondrial swelling and endoplasmic reticulum expansion. Consequently, it causes reversible neuronal damage in the dorsal cochlear nucleus without inducing significant neuronal apoptosis. In the presence of exogenous alanine or glucose, Kanamycins sulfate effectively kills drug-resistant bacteria, restores drug sensitivity of multidrug-resistant bacteria, and alleviates urinary tract and kidney infections in mice. Kanamycins sulfate can be applied to scientific research related to Mycobacterium tuberculosis, salmonellosis, brucellosis, shigellosis, urinary tract infections, and reversible neurotoxicity .

HY-W984782

Flindersine	GLUT Bacterial Fungal AMPK PPAR Reactive Oxygen Species (ROS) Apoptosis SOD	Infection Metabolic Disease Cancer
Flindersine is an alkaloid with multiple activities including antibacterial, antifungal, antitumor, and antidiabetic properties. Flindersine increases the activity of antioxidant enzymes, restores the levels of renal biomarkers, and reduces blood glucose, blood lipid, and insulin levels in diabetic rats. Flindersine inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, drug-resistant bacteria, as well as dermatophytes, filamentous fungi, and yeasts. Flindersine reduces the viability of cancer cells and induces apoptosis. Flindersine can be used in research related to breast cancer, type 2 diabetes, bacterial infections, and fungal infections .

HY-177716

Ciprofloxacin prodrug-1	Beta-lactamase Bacterial	Infection
Ciprofloxacin prodrug-1 (Compound 35) is an activated prodrug of β-lactase. Ciprofloxacin prodrug-1 exhibits good antibacterial activity against bacteria containing β-lactase (MIC = 63 nM). After being hydrolyzed by β-lactase, Ciprofloxacin prodrug-1 can release Ciprofloxacin (HY-B0356), thereby inhibiting the activity of DNA gyrase. Ciprofloxacin prodrug-1 can be used to study infections caused by enzyme-producing drug-resistant bacteria (such as uropathogenic Escherichia coli) .

HY-186019

FtsZ-IN-14	Bacterial	Infection
FtsZ-IN-14 (example XI) is a filamentous temperature-sensitive protein Z (FtsZ) inhibitor. FtsZ-IN-14 can inhibit the growth of various drug-resistant bacteria in vitro and can be used to prepare antibiotics against drug-resistant bacteria .

HY-173478

OSUAB-0284	Topoisomerase Bacterial Antibiotic	Infection
OSUAB-0284 is a bacterial topoisomerase inhibitor. OSUAB-0284 has significant anti-staphylococcal activity, especially against methicillin-resistant Staphylococcus aureus (MRSA). OSUAB-0284 exerts its antibacterial effect by inhibiting bacterial topoisomerase. OSUAB-0284 can be used to study infections caused by drug-resistant bacteria such as MRSA .

HY-178504

Lug-15	Bacterial	Infection
Lug-15 is a rapid bactericidal agent. Lug-15 exhibits strong antibacterial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. Lug-15 rapidly kills bacteria primarily through membrane disruption and had a very low propensity to induce bacterial resistance. Lug-15 demonstrates low hemolytic toxicity and significant therapeutic potential in various infection models. Lug-15 can be used for research on combating infections caused by multi-drug resistant bacteria .

HY-117742

DA-7867	Bacterial	Infection
DA-7867 is an antibacterial compound with activity against a wide range of bacteria, including drug-resistant bacteria. DA-7867 shows promising antibacterial activity against some clinically important pathogens, including drug-resistant bacteria. It is an amide analog of Tedizolid (HY-14855), reflecting the potential use of tetrazoles in the development of new antibacterial agents .

HY-149089

Antibacterial agent 138	Bacterial	Infection
Antibacterial agent 138 has excellent antibacterial activity to multi-drug resistant bacteria. Antibacterial agent 138 inhibits bacterial protein synthesis but bacterial cell walls .

HY-120235

CB-618	Beta-lactamase Bacterial	Infection
CB-618 is a β-lactamase inhibitor. CB-618 reversibly covalently inhibits Ambler class A, C, and some class D serine β-lactamases. CB-618 has weak antibacterial activity as a single agent, but it significantly enhances the antibacterial activity of Meropenem (HY-13678) against enzyme-producing Enterobacteriaceae. CB-618 can be used in research on drug-resistant bacteria .

HY-146595

FtsZ-IN-1	Bacterial	Infection
FtsZ-IN-1 is a potent FtsZ inhibitor with quinolinium ring. FtsZ-IN-1 has stronger antibacterial activity against Gram-positive bacteria with MICs of 0.5-8 μg/mL. FtsZ-IN-1 significantly causes cell elongation of B. subtilis by enhancing FtsZ polymerization. FtsZ-IN-1 exhibits low hemolytic toxicity and low tendency to induce agent resistance. FtsZ-IN-1 has against drug-resistant bacteria activity .

HY-180116

β-Lactamase-IN-11	Beta-lactamase Bacterial	Infection
β-Lactamase-IN-11 is a β-Lactamase Inhibitor with an IC₅₀ of 30.37 μM. β-Lactamase-IN-11 exhibits significant antibacterial activity against Staphylococcus aureus and Pseudomonas aeruginosa, demonstrating potential for combating various drug-resistant bacteria. β-Lactamase-IN-11 can be used for studying infections caused by enzyme-producing drug-resistant bacteria .

HY-106852A

KP 736 sodium	Bacterial	Infection
KP 736 sodium is a broad-spectrum antibacterial agent. KP 736 sodium exhibits excellent broad-spectrum anti Gram negative bacterial activity in vitro, especially effective against Pseudomonas aeruginosa and multiple drug-resistant bacteria. KP 736 sodium can be used for research on bacterial infections .

HY-178975

β-Lactamase-IN-10	Beta-lactamase Bacterial	Infection
β-Lactamase-IN-10 (Compound CB1) is a dual-metal β-lactamase (MLB) and serine β-lactamase (SLB) inhibitor. β-Lactamase-IN-10 exhibits antibacterial (antibacterial) activity against various drug-resistant bacteria. β-Lactamase-IN-10 can be used in the research of Gram-negative superbug infections .

HY-179709

NDM-1-IN-12	Beta-lactamase Bacterial	Infection
NDM-1-IN-12 (Compound 10c) is an inhibitor of NDM-1 metallo-β-lactamase, with an IC₅₀ value of 9 nM. NDM-1-IN-12 effectively reverses bacterial resistance to β-lactam antibiotics and shows an additive effect when used in combination with antibiotics and SBL inhibitors. NDM-1-IN-12 can be used in the research of anti-multi-drug resistant bacteria .

HY-180151

Antibacterial agent 306	Lactate Dehydrogenase Bacterial DNA/RNA Synthesis Reactive Oxygen Species (ROS)	Infection
Antibacterial agent 306 (Compound 8c), a lactate dehydrogenase inhibitor, is a highly effective antibacterial agent, especially effective against Gram-positive bacteria. Antibacterial agent 306 exhibits MIC against Staphylococcus aureus of as low as 1 μg/mL. Antibacterial agent 306 can not only damage membrane integrity and block the replication of DNA by intercalation, but also make reactive oxygen species (ROS) burst. Antibacterial agent 306 can be used for research on anti-multi-drug resistant bacteria .

HY-W780694

PD 124816	Bacterial Antibiotic DNA/RNA Synthesis Topoisomerase	Infection
PD 124816 is an orally active fluoroquinolone antibiotic. PD 124816 exerts broad-spectrum antibacterial effects by inhibiting DNA gyrase (topoisomerase IV), and it has no cross-resistance with commonly used antibiotics. PD 124816 is effective against both Gram-positive and Gram-negative bacteria (MIC₉₀ ≤ 0.06 μg/mL), and the MIC₉₀ for anaerobic bacteria (Peptostreptococcus fragi) is 1 μg/mL. PD 124816 exhibits complete bactericidal activity in a mouse model of Mycobacterium leprae infection. PD 124816 can be used for studying mixed infections and infections caused by drug-resistant bacteria .

HY-W154247

IP6C	Bacterial	Infection
IP6C is a specific inhibitor and phage sensitizer targeting type II Thoeris systems. IP6C competitively binds to histidine in the catalytic pocket of ThsB, blocks the production of the His-ADPR alarm signal and inhibits ThsA activation, thereby relieving bacterial stasis of phage replication. IP6C selectively resensitizes drug-resistant bacteria carrying type II Thoeris systems (such as Pseudomonas aeruginosa) to phage lysis, without affecting other bacteria, and shows no toxicity to mice and human cell lines. IP6C significantly improves the survival rate of infected mice, and can be used to overcome bacterial phage defense mechanisms and study Pseudomonas aeruginosa infections . Thoeris system: (named after the Egyptian goddess of fertility and protection), is a widespread anti-phage immune defense system in bacteria and archaea. Thoeris system belongs to the "Abortion Infection (Abi)" mechanism of bacteria: when an individual bacterium detects phage invasion, it initiates a suicide program and dies, thereby blocking phage replication and spread, and protecting the surrounding bacterial population from infection.

Cat. No.	Product Name

HY-L939

Antibacterial Lead-like compound library	10855 compounds
The rising prevalence of multidrug-resistant and extensively drug-resistant bacteria, combined with emerging resistance mechanisms and the limitations of existing antibacterial drugs, creates an urgent need for novel antibacterial agents. Antibacterial compound libraries serve as key tools to support antibacterial drug screening and development. This library features structurally diverse compounds, including small-molecule scaffolds and natural product derivatives, and exhibits diverse antibacterial mechanisms of action. For example, these compounds exert antibacterial effects by disrupting bacterial cell structures, interfering with bacterial metabolic processes, and inhibiting nucleic acid synthesis. The derivation of scaffold structures enhances their activity against drug-resistant bacteria and their selectivity against different types of bacteria. This library can be used for the high-throughput screening of novel antibacterial drug candidates and the identification of potent compounds against drug-resistant and multidrug-resistant bacteria. Additionally, it provides a reference for compound structural modification, enabling further in-depth research on the structure-activity relationships(SARs) of antibacterial drugs. It can also be applied to the exploration of bacterial resistance mechanisms and reversal strategies, as well as the discovery of antibacterial molecules that inhibit efflux pumps and restore drug susceptibility. The library contains 10855 structurally diverse drug-like compounds. Its core compound sources include analogs of known antifungal active moleculeswith a similarity score of ≥ 0.6. MCE has collected more than 1900 antibacterial molecules. All screened compounds conform to lead-like physicochemical properties, providing valuable support for the research and development of novel antibacterial drugs.

Antibacterial Lead-like compound library

10855 compounds

The rising prevalence of multidrug-resistant and extensively drug-resistant bacteria, combined with emerging resistance mechanisms and the limitations of existing antibacterial drugs, creates an urgent need for novel antibacterial agents. Antibacterial compound libraries serve as key tools to support antibacterial drug screening and development.

This library features structurally diverse compounds, including small-molecule scaffolds and natural product derivatives, and exhibits diverse antibacterial mechanisms of action. For example, these compounds exert antibacterial effects by disrupting bacterial cell structures, interfering with bacterial metabolic processes, and inhibiting nucleic acid synthesis. The derivation of scaffold structures enhances their activity against drug-resistant bacteria and their selectivity against different types of bacteria. This library can be used for the high-throughput screening of novel antibacterial drug candidates and the identification of potent compounds against drug-resistant and multidrug-resistant bacteria. Additionally, it provides a reference for compound structural modification, enabling further in-depth research on the structure-activity relationships(SARs) of antibacterial drugs. It can also be applied to the exploration of bacterial resistance mechanisms and reversal strategies, as well as the discovery of antibacterial molecules that inhibit efflux pumps and restore drug susceptibility.

The library contains 10855 structurally diverse drug-like compounds. Its core compound sources include analogs of known antifungal active moleculeswith a similarity score of ≥ 0.6. MCE has collected more than 1900 antibacterial molecules. All screened compounds conform to lead-like physicochemical properties, providing valuable support for the research and development of novel antibacterial drugs.

Cat. No.	Product Name	Target	Research Area

HY-P1939

Cyclo(L-Leu-L-Pro) Cyclo(L-prolyl-L-leucyl)	Fungal Bacterial Influenza Virus	Infection
Cyclo(L-Leu-L-Pro) is a cyclic dipeptide with broad-spectrum antibacterial, antiviral and antifungal activities. Its biological activity is highly dependent on the stereoconfiguration and is widely present in microbial metabolites. Cyclo(L-Leu-L-Pro) efficiently and specifically inhibits the production of aflatoxin by Aspergillus flavus. The cis configuration of Cyclo(L-Leu-L-Pro) (cis-cyclo(L-Leu-L-Pro)) has broad-spectrum antibacterial activity against multi-drug resistant bacteria and significantly inhibits the influenza A virus H3N2 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W984782

Flindersine	Structural Classification Alkaloids Rutaceae Quinoline Alkaloids Plants Haplophyllum tuberculatum (Forssk.) A.Juss. Source Classification	GLUT Bacterial Fungal AMPK PPAR Reactive Oxygen Species (ROS) Apoptosis SOD
Flindersine is an alkaloid with multiple activities including antibacterial, antifungal, antitumor, and antidiabetic properties. Flindersine increases the activity of antioxidant enzymes, restores the levels of renal biomarkers, and reduces blood glucose, blood lipid, and insulin levels in diabetic rats. Flindersine inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, drug-resistant bacteria, as well as dermatophytes, filamentous fungi, and yeasts. Flindersine reduces the viability of cancer cells and induces apoptosis. Flindersine can be used in research related to breast cancer, type 2 diabetes, bacterial infections, and fungal infections .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks